Red Light Holland to Rebrand as Rhelion Life Sciences Amid Psychedelic Drug Development Surge

Strategic Rebranding Marks Transition to Specialized Life Sciences Entity

Red Light Holland's evolution into Rhelion Life Sciences signifies a deliberate shift towards a focused clinical and research-led enterprise within the psychedelic medicine sector. The rebranding, subject to Canadian Securities Exchange approval, aims to establish the company as a science-driven natural psychedelic drug discovery and development organization. Details about the effective date and any changes to trading symbols will be provided in future announcements.

CEO Todd Shapiro emphasized that the rebrand is more than a name change, describing it as "everything we have been building toward when it comes to increasing responsible and standardized psychedelic access." The new identity is designed to better communicate with patients, researchers, partners, regulators, and investors amid accelerating momentum and heightened investor interest in the psychedelic sector, highlighted by significant pharmaceutical industry involvement.

Filament Health Acquisition Strengthens PEX010 Development Platform

The rebranding follows the completion of Red Light Holland's acquisition of Filament Health Corp., which now forms the foundation of the company’s drug development strategy. Through this wholly owned subsidiary, the company is advancing naturally derived psilocybin drug candidates, focusing on PEX010, a patented botanical drug candidate. This acquisition has expanded pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities to support ongoing psilocybin development.

Filament employs proprietary extraction, purification, and stabilization techniques to produce a potent, standardized, and patented botanical drug product with consistent composition across all doses, studies, and research sites. This consistency is secured by an extensive international patent portfolio, ensuring that research findings can be attributed to the compound itself rather than batch variations — a critical factor for reproducibility in clinical and academic research.

Expanded Standardized Dosing Range Enhances PEX010 Research Utility

Filament Health recently introduced a 0.5 mg dose of PEX010, complementing existing 1, 5, and 25 mg strengths to create a standardized dosing range from microdosing to full therapeutic levels. This expanded portfolio meets diverse research needs across academic and clinical settings, offering consistency for rigorous comparative studies and accurate attribution of outcomes.

PEX010 demonstrates a 36-month shelf life, supporting dependable global supply chains and institutional stockpiling for extended research programs. This stability is vital for academic institutions and research networks operating across multiple jurisdictions with varying logistics and storage conditions. The dosing expansion and stability underscore ongoing demand for pharmaceutical-grade, naturally derived psilocybin and the growing role of PEX010 in academic and clinical research.

Robust Global Clinical and Academic Research Distribution

PEX010 has been distributed to over 80 academic and philanthropic research studies worldwide, including prestigious institutions such as Imperial College, Johns Hopkins University, University of California San Francisco, and McGill University. This extensive distribution network reflects Filament’s scientific credibility and the increasing institutional acceptance of psilocybin as a valid subject for rigorous neuroscience and psychiatry research.

The expanded clinical and research footprint demonstrates operational maturity achieved through the Filament acquisition. The company's capability to supply a standardized pharmaceutical-grade psilocybin product to multiple leading research institutions simultaneously aligns with quality standards expected by major academic medical centers. This network also provides insights into emerging research trends and clinical applications for naturally derived psilocybin.

Sector Growth and Pharmaceutical Industry Engagement

The rebranding announcement coincides with heightened activity in the psychedelic sector. On July 16, 2026, a day before Red Light Holland’s announcement, Eli Lilly and Company disclosed plans to acquire AtaiBeckley for up to US$3.8 billion. This transaction is among the largest in the sector to date and signals increasing interest from major pharmaceutical companies in clinically de-risked psychedelic assets.

Red Light Holland’s leadership noted that this sector momentum influenced the timing of the rebrand. The company aims to position Rhelion Life Sciences as a competitive player with a "world-class drug development platform, a growing program, and a bold vision for the future of natural psychedelic medicine." The rebrand outlines a strategy to "build genuine, de-risked value for our shareholders" by advancing PEX010 through clinical development pathways that mitigate regulatory uncertainty and enhance prospects for drug approval and commercialization.

Operations Within the Netherlands’ Legal Adult-Use Psychedelic Market

In addition to clinical and research initiatives, Red Light Holland (soon Rhelion) operates in the Netherlands’ regulated adult-use market for psychedelic products. The company supports voluntary data collection and research efforts aimed at advancing scientific knowledge of natural psychedelics. This presence in a regulated adult-use jurisdiction provides real-world market experience and consumer behavior insights to inform product development.

The company has previously launched the iMicro app in the Netherlands to facilitate voluntary data gathering. Forward-looking statements indicate that future trial designs will incorporate data collected through this platform, representing a hybrid approach that integrates market-based data with academic clinical trial design to gather evidence across various use contexts and populations.

Strong Patent Protection and Intellectual Property Strategy

Rhelion’s competitive edge relies heavily on intellectual property protections surrounding PEX010 and Filament’s proprietary extraction, purification, and stabilization processes. The announcement highlights that PEX010’s consistency is safeguarded by a broad international patent portfolio covering the botanical drug candidate and manufacturing methods enabling standardized large-scale production.

Protecting botanical extraction and stabilization techniques is especially important in the psychedelic field, where naturally derived compounds face unique manufacturing and quality assurance challenges compared to synthetic alternatives. Filament’s proprietary method for producing standardized, shelf-stable natural psilocybin creates a defensible competitive advantage by limiting competitors’ ability to replicate these manufacturing benefits, potentially securing a durable market position for psilocybin therapeutics.

Corporate Identity Aligns With Evolving Global Regulatory Landscape

The Rhelion brand reflects management’s intent to better convey the company’s mission to patients, researchers, partners, regulators, and investors amid increasing scientific and regulatory scrutiny of psychedelic compounds in major markets. Regulatory agencies in the U.S., Canada, and Europe are establishing clinical investigation pathways for psychedelic-derived therapeutics, creating a legitimate institutional framework for companies like Rhelion.

Transitioning from the Red Light Holland name, associated with the Netherlands’ adult-use cannabis and other substance markets, to Rhelion underscores a strategic focus on scientific and clinical aspects. This rebranding helps distance the company from commercial cannabis associations and positions it more clearly within pharmaceutical and clinical research sectors, facilitating partnerships, regulatory engagement, and potential strategic deals with major pharmaceutical companies.

Forward-Looking Research Program and Scientific Advisory Board Plans

The announcement outlines Rhelion’s intention to pursue an "ambitious new research and development program" alongside ongoing PEX010 development. Although specific details are not disclosed, forward-looking statements reference upcoming announcements regarding clinical trial plans, the formation of a Scientific Advisory Board, and expansion of clinical, research, and compassionate use networks. The company also anticipates strategic opportunities and potential value realization pathways without specifying timelines.

The formation of a Scientific Advisory Board is anticipated, though forward-looking statements caution that it may not materialize as planned or prospective members may decline invitations. This indicates active recruitment of scientific and clinical experts to guide the research program, with the final composition yet to be announced.

Risk Factors and Regulatory Challenges

The announcement’s forward-looking statements section identifies material risks, including the rebrand’s dependency on Canadian Securities Exchange approval, possible delays in clinical trial starts, failure to secure necessary regulatory or ethics approvals, and risks related to realizing benefits from the Filament acquisition. Additional risks involve PEX010 and other drug candidate development, regulatory changes, and evolving psychedelic substance laws.

Investors should recognize that sector momentum and pharmaceutical interest in psychedelic assets remain uncertain. The company warns that "sector momentum, including third party merger and acquisition activity, may not continue or may not benefit the Company." Risks related to financing availability and broader economic, market, and business conditions are also noted. For comprehensive risk details, readers are directed to the company’s continuous disclosure documents available on SEDAR+.